Associated Papers
Recurrent cancer-associated ERBB4 mutations are transforming and confer resistance to targeted therapies.
Ojala VK et al.
Molecular Oncology, 2025
Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer.
Fasching PA et al.
Npj Breast Cancer, 2024
39003306 (PubMed )
Supplement: 41523_2024_667_MOESM1_ESM.pdf
Molecular Features of Resected Melanoma Brain Metastases, Clinical Outcomes, and Responses to Immunotherapy.
Vasudevan HN et al.
Jama Network Open, 2023
37589977 (PubMed )
Supplement: jamanetwopen-e2329186-s001.xlsx › TableS1
ERBB family fusions are recurrent and actionable oncogenic targets across cancer types.
Schubert L et al.
Frontiers in Oncology, 2023
37168365 (PubMed )
Supplement: Table_4.xlsx › ERBB4_mutations
Ensemble of nucleic acid absolute quantitation modules for copy number variation detection and RNA profiling.
Wu LR et al.
Nature Communications, 2022
35379811 (PubMed )
Supplement: 41467_2022_29487_MOESM4_ESM.xlsx › 175_plex_primers
Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer.
Sivapiragasam A et al.
Cancer Medicine, 2021
33314633 (PubMed )
Supplement: CAM4-10-53-s002.xlsx › Sheet1
Next-generation sequencing analysis of endometrial screening liquid-based cytology specimens: a comparative study to tissue specimens.
Akahane T et al.
Bmc Medical Genomics, 2020
32652986 (PubMed )
Supplement: 12920_2020_753_MOESM2_ESM.xlsx › Sheet1
Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study.
Cremolini C et al.
Esmo Open, 2019
Copy number signatures and mutational processes in ovarian carcinoma.
Macintyre G et al.
Nature Genetics, 2018
30104763 (PubMed )
Supplement: NIHMS78219-supplement-3.xlsx › mutated_cases
Frequency, impact and a preclinical study of novel ERBB gene family mutations in HER2-positive breast cancer.
Elster N et al.
Therapeutic Advances in Medical Oncology, 2018
Non-reproducible sequence artifacts in FFPE tissue: an experience report.
Ofner R et al.
Journal of Cancer Research and Clinical Oncology, 2017
Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers.
Miller CA et al.
Nature Communications, 2016
27502118 (PubMed )
Supplement: ncomms12498-s13.xls › s11_Sheet1.tsv
Pan-Cancer Analysis of Mutation Hotspots in Protein Domains.
Miller ML et al.
Cell Systems, 2015
Select a paper to view details